In former studies, we established the association between low ALT and worse clinical outcomes in other patient populations suffering from different, hematologic and solid malignancies: myelodysplastic syndrome [13], chronic lymphocytic leukemia [16], prostate adenocarcinoma [14] and bladder cancer [15]. This evidence concerns the gene GPT and urinary bladder cancer.